Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749

MT Newswires Live04-01

Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.

The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.

The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.

Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.

Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.

Price: 15.48, Change: +0.40, Percent Change: +2.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524973911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-01 01:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524973911","market":"fut","top_or_hot":-1,"title":"Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.</p><p>The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.</p><p>The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.</p><p>Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.</p><p>Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.</p><p>Price: 15.48, Change: +0.40, Percent Change: +2.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-01 01:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.</p><p>The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.</p><p>The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.</p><p>Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.</p><p>Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.</p><p>Price: 15.48, Change: +0.40, Percent Change: +2.63</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524973911","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524973911","pubTimestamp":1743443736,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.Price: 15.48, Change: +0.40, Percent Change: +2.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4557":"大麻股","TEVA":"梯瓦制药","BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团","BK4588":"碎股"},"translate_title":"梯瓦表示精神分裂症试验调查结果显示患者对TEV-'749的满意度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9},"content_text":"Teva Pharmaceutical Industries' (TEVA) US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.Price: 15.48, Change: +0.40, Percent Change: +2.63","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524973911","isCrawlerRequest":true}